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ABSTRACT
Male breast cancer (MBC) is a rare disease. Due to its rarity, MBC research and 
clinical approach are mostly based upon data derived from its largely known female 
counterpart. We aimed at investigating whether MBC cases harbor somatic alterations 
of genes known as prognostic biomarkers and molecular therapeutic targets in female 
breast cancer.
We examined 103 MBC cases, all characterized for germ-line BRCA1/2 mutations, 
for somatic alterations in PIK3CA, EGFR, ESR1 and CCND1 genes.
Pathogenic mutations of PIK3CA were detected in 2% of MBCs. No pathogenic 
mutations were identified in ESR1 and EGFR. Gene copy number variations (CNVs) 
analysis showed amplification of PIK3CA in 8.1%, EGFR in 6.8% and CCND1 in 16% 
of MBCs, whereas deletion of ESR1 was detected in 15% of MBCs. Somatic mutations 
and gene amplification were found only in BRCA1/2 mutation negative MBCs.
Significant associations emerged between EGFR amplification and large tumor 
size (T4), ER-negative and HER2-positive status, between CCND1 amplification and 
HER2-positive and MIB1-positive status, and between ESR1 deletion and ER-negative 
status.
Our results show that amplification of targetable oncogenes is frequent in 
BRCA1/2 mutation negative MBCs and may identify MBC subsets characterized 
by aggressive phenotype that may benefit from potential targeted therapeutic 
approaches.
INTRODUCTION
Male breast cancer (MBC) is a rare disease, 
representing less than 1% of all breast cancers (BCs) 
and less than 1% of all cancers in men [1]. Germ-line 
mutations in the high-penetrance BC genes, BRCA1 and, 
mainly, BRCA2 play a major role in MBC susceptibility 
and about 10% of MBCs are associated with mutations in 
these genes [2].
Due to its rarity, MBC research and patient 
management are mostly based upon data derived from 
its largely known female counterpart. To date treatment 
strategies for MBC patients generally follow those for 
female patients. As most breast cancers in men are hormone 
receptor-positive, current therapeutic options mainly include 
hormone therapy that is usually recommended for MBC 
patients following the same recommendations as hormone-
dependent-BC in women [3].
MBC shares some similarities with post-menopausal 
estrogen receptor (ER)-positive female breast cancer 
(FBC), however increasing evidence indicates that, on 
clinical and molecular level, MBC may be a heterogeneous 
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disease, different from FBC [4–6]. Compared to FBC, 
MBC occurs later in life, with higher stage, lower grade 
and more estrogen/progesterone receptor (ER/PR) 
positivity [7–8].
To date, the majority of MBC studies focused 
on germ-line mutational analysis and gene expression 
profiling, while there are only few studies investigating 
somatic alterations in MBCs [4–5, 9]. By contrast, 
accumulating data have provided a landscape of 
somatic alterations with possible clinical relevance and 
several somatic mutations with potential prognostic and 
therapeutic significance are known in FBC [10–13]. In 
addition to gene mutations, gene copy number variations 
(CNVs) have been reported as an important mechanism 
in the development and progression of cancer and could 
serve as potential prognostic biomarkers and molecular 
therapeutic targets [14–18].
A comprehensive portrait of the genetic landscape 
of FBCs has demonstrated that Phosphatidylinositol 
3-kinase gene (PIK3CA) is the most commonly mutated 
gene and two mutation hotspot regions in exons 9 and 20 
have been identified [19–20]. Mutations of PIK3CA have 
been suggested to have prognostic value and to confer 
resistance to hormone therapy and to downstream mTOR 
inhibitors [11, 21]. The proportion of FBCs exhibiting 
PIK3CA mutations ranges between 20-25%, and, notably, 
mutations occur approximately in 40% of ER-positive 
FBCs [11, 19–23]. To date four studies investigated 
PIK3CA mutations in MBC [6, 24–26]. Overall PIK3CA 
mutation frequency observed in MBC was lower than 
FBC. In addition to somatic mutations, gene amplification 
of PIK3CA is reported in about 10% of FBC [27–29]. 
Among targetable genes, the epidermal growth factor 
receptor (EGFR) is one of the first important molecular 
targets identified in BC [10, 30–31]. EGFR gene CNVs in 
FBC range from 8 to 10%, [32–33] while the proportion 
of FBCs exhibiting EGFR somatic mutations ranges from 
2 to 15% [34–36]. Notably a higher rate of activating 
EGFR mutations is detected in BRCA1/2 mutation positive 
tumors, supporting the hypothesis that carcinogenic 
processes may be dependent on the germ-line phenotype 
[34]. CCND1 is an estrogen-responsive gene that enhances 
ER-mediated gene transcription. The product of CCND1, 
cyclin D1, provide growth advantage to cancer cells 
and contribute toward resistance to endocrine therapy 
in ER-positive cancers. In FBC, CCND1 is amplified in 
5–20% of primary BCs, typically ER-positive BC, and is 
a prognostic biomarker with a potential therapeutic role 
[12, 13, 15, 37, 38]. As MBC is an estrogen-driven disease 
and is most frequently ER-positive, the investigation of 
CCND1 alterations might be relevant in male breast 
tumors [8]. Recently, CCND1 amplification has been 
shown to be an independent prognostic factor in MBC 
[39]. Somatic mutations of CCND1 are not a frequent 
alteration in cancer, and, in particular have not been 
reported in BC [19, 40].
Interestingly, crosstalk between ER and PI3K 
pathway may increase estrogen-induced and ligand-
independent ER transcriptional activity [41]. Recurrent 
activating mutations of ESR1, the gene encoding the 
estrogen receptor alpha (ERα), have been identified in 
hormone therapy-refractory ER-positive metastatic FBC 
[42–44]. CNVs of ESR1 have been largely investigated 
in FBC, although with controversial results [45]. 
Data emerging from studies evaluating ESR1 somatic 
alterations in MBC suggest that ESR1 alterations may be 
gender specific [39].
Although knowledge on somatic landscape of 
MBC is increasing, comprehension on the role of somatic 
alterations of specific genes with potential prognostic and 
therapeutic significance need to be further investigated in 
MBCs characterized for BRCA1/2 mutations. In this study, 
we focused on somatic mutations and CNVs of PIK3CA, 
EGFR, ESR1 and CCND1 genes by examining a large 
series of MBCs screened for BRCA1/2 germ-line mutations.
RESULTS
Mutational screening
Mutational screening of PIK3CA was performed 
in 102 primary breast cancers and one lymph-node 
metastasis. Two mutations, both located in exon 9, were 
detected: the c.1633G>A (p.E545K) was identified in 
two MBC cases and the c.1634A>C (p.E545A) in two 
additional cases (Table 1). In these latter cases, a second 
mutation, c.1658_1659delGTinsC (p.S553Tfs*7), also 
located in exon 9, was detected (Figure 1).
To exclude that PIK3CA pseudogene, retaining high 
homology with the sequence of exon 9 (https://blast.ncbi.
nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch), might 
affect PIK3CA mutation screening, we performed 
amplification and sequencing analysis using primers 
specific for the PIK3CA gene and pseudogene 
(Supplementary Table S1). This analysis showed that both 
c.1634G>A and c.1658_1659delGTinsC were due to the 
pseudogene amplification (Figure 2).
Overall, PIK3CA mutations were identified in 2 out 
of 102 (2%) primary MBCs examined. Both these MBCs 
were from BRCA1/2 mutation negative patients with no 
family history of BC, were invasive ductal carcinomas, 
and presented with high grade (G3), ER-positive, HER2-
negative and lymph node positive status.
An additional PIK3CA mutation located in exon 20, 
the c.3140A>G (p.H1047R), was detected in the metastatic 
lymph node sample examined from a MBC case whose 
primary tumor was PIK3CA mutation negative (Table 1).
Mutational analysis of EGFR identified two 
synonymous variants (Table 1): the c.2361G>A (p.Q787Q) 
occurring in 15 of 102 cases (14.7%), and c.2748C>T 
(p.N916N) occurring in one case. Mutational analysis 
of ESR1 identified one synonymous variant c.975G>C 
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Table 1: Summary of results from PIK3CA, EGFR and ESR1 mutational analysis
Gene Exon Nucleotide change Amino acid change Sample
PIK3CA 9 c.1633G>A p.E545Ka primary tumor
PIK3CA 9 c.1634A>C; c.1658_1659delGTinsC p.E545Aa; p.S553Tfs*7a primary tumor
PIK3CA 20 c.3140A>G p.H1047Ra metastatic lymph node
EGFR 20 c.2361G>A p.Q787Qb primary tumor
EGFR 23 c.2748C>T p.N916Nb primary tumor
ESR1 4 c.975G>C p.P325Pb primary tumor
a pathogenic mutation;
b synonymous variant.
All mutations and variants identified are recorded on COSMIC database (http://cancer.sanger.ac.uk/cosmic).
Figure 1: PIK3CA mutations identified in MBCs. Partial electropherograms from direct sequencing of PIK3CA exon 9 in a case harboring 
the c.1633G>A (p.E545K) mutation A. and in a case harboring c.1634A>C (p.E545A) and 1658delGTinsC (p.S553Tfs*7) mutations B.
Figure 2: Specific sequencing of PIK3CA exon 9 and pseudogene. Partial electropherograms from direct sequencing of DNA 
region using primers specific for PIK3CA exon 9 A. and for pseudogene B.
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(p.P325P) in 15/70 cases (21.4%). No pathogenic mutations 
were identified in ESR1 and EGFR genes (Table 1).
Gene copy number variation analysis
Overall, gene CNV analysis showed amplification 
of PIK3CA, EGFR and CCND1, and deletion of ESR1. 
Specifically, amplification of PIK3CA was detected 
in 6/74 (8.1%), EGFR in 5/74 (6.8%) and CCND1 in 
10/62 (16%) of the MBC cases analyzed. Overall, gene 
amplifications were detected in MBCs from BRCA1/2 
mutation negative patients. Deletion of ESR1 was shown 
in 11/73 (15%) of the cases, including one case with 
BRCA2 germ-line mutation. Co-amplification of PIK3CA, 
EGFR and CCND1 was observed in two MBC cases 
and co-amplification of EGFR and CCND1 in one case. 
Furthermore, one case showed both PIK3CA mutation and 
CCND1 amplification.
The overall CNV profile was investigated by 
unsupervised hierarchical clustering analysis performed 
on 41 MBC cases, for which data on CNVs of all genes 
examined were available. Hierarchical cluster analysis 
revealed two groups of cases (Figure 3). One group 
characterized by no CNV or CNV in only one gene, mainly 
CCND1 amplification, and a second group characterized 
by CNVs in multiple genes. Notably, this second group 
included cases characterized by aggressive pathologic 
features, including high tumor grade (G3), large tumor 
size (T4) and lymph node involvement.
Associations between somatic alterations and 
clinical-pathologic features
As shown in Table 2, statistically significant 
differences emerged in the distribution of EGFR, CCND1 
and ESR1 CNVs according to ER, HER2, MIB1 and 
tumor size (T) status. In particular, CNVs of EGFR were 
associated to ER, HER2, MIB1 and T status, of CCND1 to 
HER2 and MIB1 status and of ESR1 to ER status.
By linear logistic regression analysis a statistically 
significant association was confirmed between EGFR 
amplification and ER-negative status (p=0.01), HER2-
positive status (p=0.03) and T4 (p=0.01). By using a 
stepwise logistic regression, in which ER, HER2, MIB1 
and T status were included, the dependency of these four 
characteristics in relation to EGFR amplification was 
analyzed, and only ER was selected as a significant effect 
(p=0.044). Furthermore, by linear logistic regression 
analysis significant association was confirmed between 
CCND1 amplification and HER2-positive (p=0.0005) 
and MIB1-positive (p=0.04) status, and between ESR1 
deletion and ER-negative status (p=0.01).
DISCUSSION
In this study we investigated somatic mutations and 
CNVs of PIK3CA, EGFR, CCND1 and ESR1 in a large 
series of MBCs characterized for germ-line BRCA1 and 
BRCA2 mutations. We found that gene CNVs are frequent 
Figure 3: Unsupervised hierarchical clustering analysis of CNVs in EGFR, PIK3CA, ESR1 and CCND1 genes in male 
breast tumors.
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Table 2: Frequencies of clinical-pathologic features considered in 103 primary male breast tumors crossed with gene 
copy number variations (CNVs)
Parameter Total cases (%)
Gene CNVs
PIK3CA EGFR CCND1 ESR1
amp/Na pb amp/Na pb amp/Na pb del/Na pb
FHc of breast/
ovarian cancer
 Negative 75 (72.8) 6/53
0.108
5/56
0.189
6/49
0.106
7/52
0.546
 Positive 28 (27.2) 0/21 0/18 4/13 4/21
Personal history 
of cancer
 Negative 77 (74.8) 5/56
0.648
5/56
0.189
8/46
0.647
9/50
0.302
 Positive 26 (25.2) 1/18 0/18 2/16 2/23
BRCA1/2 status
 BRCA1 mutated 2 (2) 0/1
0.673
0/1
0.789
0/1
0.528
0/1
0.872 BRCA2 mutated 9 (8.7) 0/7 0/5 0/5 1/5
 BRCA1/2 wild-
type 92 (89.3) 6/66 5/68 10/56 10/67
Hystological type
 Infiltrating 
ductal carcinoma 82 (83.7) 5/59 0.277
5/60
0.352
10/52
0.15
9/64
0.702
 Other 16 (6.3) 0/13 0/10 0/9 1/10
ER
 Negative 15 (14.8) 2/11
0.192
3/10
0.002
2/10
0.736
4/9
0.009
 Positive 86 (85.2) 4/62 2/62 8/55 7/64
PR
 Negative 24 (23.8) 1/20
0.538
3/18
0.061
5/42
0.159
3/16
0.641
 Positive 77 (76.2) 5/53 2/54 5/19 8/57
HER2
 Negative 69 (74.2) 2/46
0.051
1/46
0.012
4/41
0.019
10/53
0.201
 Positive 24 (25.8) 4/21 4/20 6/17 1/17
MIB1 (Ki67)
 Negative 60 (61.2) 1/38
0.064
0/38
0.013
2/30
0.032
8/44
0.293
 Positive 38(38.8) 5/34 5/33 8/29 3/30
Hystological 
grade
 G1+G2 61 (64.2) 4/43
0.818
2/45
0.199
4/37
0.135
8/47
0.383
 G3 34 (35.8) 2/26 3/23 5/19 2/22
Lymph nodes
 Not involved 43 (55.8) 1/29
0.249
2/34
0.487
3/24
0.517
3/31
0.513
 Involved 34 (44.2) 3/26 3/28 5/26 4/26
Tumor size
 T1-T2 67 (83.6) 3/49
0.151
2/56
0.006
6/44
0.21
9/51
0.132
 T4 13 (16.4) 2/10 3/11 3/10 0/11
a amp: amplified; del: deleted; N: number of tumors that were successfully analyzed;
b p value from Chi-square test;
c FH: Family history of breast and/or ovarian cancer.
In bold p-value <0.05, considered statistically significant.
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in BRCA1/2 mutation negative MBCs and allow for the 
identification of MBC subsets characterized by pathologic 
characteristics suggestive of aggressive phenotype. By 
contrast, somatic mutations were rarely detected and were 
identified only in PIK3CA gene. We did not detect somatic 
mutations in ESR1 and EGFR, indicating that EGFR and 
ESR1 mutations are infrequent in MBC and confirming 
recent data showing no deleterious somatic mutations of 
these genes in MBC [6].
In our series PIK3CA mutations were identified in 
2% of MBCs. Our data indicate a lower PIK3CA mutation 
frequency compared with previous data on MBC. PIK3CA 
mutations have been reported in 18-20% of MBCs, not 
characterized for BRCA1/2 mutation status, and in about 
10% of familial BRCA1/2 mutation negative MBCs 
[6, 24–26]. Though differences in PIK3CA mutation 
frequency may be due to different screening methods and 
sample selection criteria, it is worth noting that our results 
refer to a MBC series that represents the twice of those 
previously reported and included hereditary, familial and 
sporadic cases, all characterized for BRCA1/2 mutation 
status. Overall, in our series PIK3CA mutations were 
identified in BRCA1/2 mutation negative MBCs, thus 
confirming the hypothesis that PIK3CA mutation status is 
dependent on germ-line genotypes of MBC [25–26].
We detected the co-existence of two 
PIK3CA mutations, c.1634G>A (p.E545A) and 
c.1658_1659delGTinsC (p.S553Tfs*7) both located in 
exon 9, in two independent MBC cases. The concurrence 
of these two somatic mutations has been previously 
reported in large B cell lymphoma and non-small cell 
lung cancer [46–47]. Moreover, the concurrence of these 
mutations as germ-line mutations has been suggested to 
predispose to Cowden and Cowden like syndromes [48]. 
Double mutations in PIK3CA are rare phenomena [49]. 
To exclude that a pseudogene of PIK3CA located on 
chromosome 22q11.2 and that retains about 95% homology 
with the sequence of PIK3CA exons 9-13 (https://blast.
ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch), 
might have influenced the accuracy of mutation detection, 
we performed true-specific PIK3CA and pseudogene 
sequencing analysis. These analyses showed that both 
c.1634A>C (p.E545A) and c.1658_1659delGTinsC 
(p.S553Tfs*7) were due to the pseudogene amplification. 
Similar observations have been reported in previous 
studies [50–52]. Therefore, when interpreting data 
corresponding to PIK3CA mutations, attention should be 
given to the possible co-amplification of PIK3CA gene and 
its pseudogene.
Interestingly, we detected PIK3CA c.3140A>G 
(p.H1047R) hotspot activating mutation in a metastatic 
lymph node of a MBC case that did not harbor PIK3CA 
mutation in the corresponding primary breast tumor. A 
different PIK3CA mutation status between primary tumors 
and corresponding metastatic lesions has been previously 
reported in FBC [53–54], indicating that PIK3CA 
mutations may be acquired during tumor progression. 
This finding may be relevant for clinical management, 
suggesting the need of assessing PIK3CA mutation status 
in metastatic lesions for the selection of PIK3CA inhibitor 
therapy.
We reported the occurrence of PIK3CA amplification 
at higher frequency than that previously reported in MBC 
[26]. The frequency of PIK3CA amplification found in our 
study is consistent with that reported in FBC [27–29]. As 
for PIK3CA mutations, PIK3CA amplification was found 
in BRCA1/2 mutation negative MBCs.
In our MBC series EGFR amplification was 
found at a higher frequency compared to previous data 
on MBC [26, 39] and FBC [32–33]. Furthermore, we 
showed that EGFR amplification was associated with 
ER-negative status, HER2-positive status and large tumor 
size (T4). These findings suggest that EGFR amplification 
could represent a prognostic marker in MBC and could 
identify a subset of MBC patients at high risk for adverse 
prognosis. Our data also suggest that this subset of MBCs 
(i.e. ER-negative and HER2-positive) might benefit 
from target therapy. Interestingly, there is evidence 
showing that therapies combining HER2 inhibitors with 
EGFR inhibitors, such as trastuzumab with lapatinib, 
may produce promising results in MBC treatment [55]. 
Overall, the association between EGFR amplification 
and ER-negative status suggest that EGFR signaling 
pathway may play a role in male breast carcinogenesis, 
mainly in estrogen-insensitive breast tumors. Interestingly, 
association between EGFR amplification and ER-negative 
status was also reported in FBC [32].
CCND1 amplification was the most frequent 
CNV observed in our MBC series, thus supporting the 
hypothesis that this gene may play a relevant role in male 
breast carcinogenesis, particularly in BRCA1/2 mutation 
negative cases. Our results are in agreement with previous 
data showing that CCND1 was one of the genes that most 
frequently showed copy number gain in MBC [39]. In our 
series, CCND1 amplification identified a subset of MBCs 
characterized by HER2-positive and MIB1-positive status, 
pathologic features suggestive of aggressive phenotype. 
These findings are in line with the function of CCND1 
protein product and are consistent with previous data 
showing that MBCs with CCND1 copy number gain 
tended to have a higher mean mitotic count compared 
to tumors without CCND1 amplification [39]. Notably, 
CCND1 amplification seems to be an independent 
prognostic factor in MBC correlating with poor survival 
[39]. Amplification of CCND1 has also been associated 
with poor prognosis in ER-positive FBC [12, 37]. As 
CCND1 is an estrogen-responsive gene, one possible 
mechanism by which its amplification could lead to a poor 
prognosis is by conferring resistance to hormone therapy 
[13, 56]. These findings may acquire great importance in 
MBC, for which endocrine therapy is the most common 
treatment [3].
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ESR1 deletion was reported at high frequency in our 
MBC series. Our results are consistent with data reporting 
gene deletion in MBC [39] and confirm that ESR1 
amplification is not a characteristic alteration of MBC. By 
contrast, ESR1 amplification has been reported, although 
with controversial results, in FBC in which ESR1 deletion 
does not appear to be a significant event [45]. In our series, 
a significant association emerged between ESR1 gene 
deletion and ER-negative status. Interestingly several data 
suggest that low-level of ESR1 expression may be one of 
the mechanisms responsible for tamoxifen resistance in 
ER-positive FBC [57]. These observations confirm the 
utility of our results in the identification of MBC subsets 
that may need specific therapeutic approach.
In agreement with the hypothesis that tumors rising 
on gene amplification are more likely to develop multiple 
amplifications as they have greater genetic instability 
[15], in this study we identified co-amplification of genes 
analyzed. By cluster analysis, we identified a group of 
cases characterized by co-amplification of two or more 
genes, suggesting the need to develop new therapeutic 
strategies involving multiple targets.
Overall, our data indicate that genes known to 
be important prognostic biomarkers and molecular 
therapeutic targets in FBC are also important in MBC. For 
instance, adjuvant trastuzumab, a monoclonal antibody 
that selectively targeted HER2 and is used as therapeutic 
agent in HER2-positive FBCs, can be considered for high-
risk HER2-positive MBCs [58]. However, differences 
emerged between male and female breast cancers, 
emphasizing the importance of identifying biomarkers 
based on research in MBC.
In conclusion our results showed that CNVs of 
PIK3CA, EGFR, CCND1 and ESR1 genes may play 
a relevant role in male breast carcinogenesis and could 
lead to the identification of specific molecular profiles. 
In particular, amplification of targetable oncogenes is 
frequent in BRCA1/2 mutation negative MBCs and may 
identify biomarkers relevant for clinical management and 
targeted therapeutic approach.
MATERIALS AND METHODS
Patients and genomic DNA
A series of 103 primary male breast tumors was 
included in the study. A metastatic lymph node sample 
was available for one case and was also included in the 
analyses. All MBC cases were characterized for germ-line 
BRCA1 and BRCA2 mutations and for the main clinical-
pathologic features, including: age at diagnosis, family 
and personal history of cancer, tumor histological type, 
grade (G), nodal status, tumor size (T), estrogen receptor 
(ER), progesterone receptor (PR), MIB1 (Ki67) and 
HER2 expression (Table 2). The expression of ER, PR, 
and Ki67/MIB1 was scored based on the percentages of 
positive nuclei (ER/PR positive if >10%; Ki67/MIB1 high 
if >20%) over the total number of counted cancer cell 
nuclei HER2 positivity was defined as a score of 3+ using 
immunohistochemistry (IHC) test, or amplification shown 
by fluorescence in situ hybridization (FISH), in equivocal 
cases [59–60].
Genomic DNA was isolated from microdissected 
formalin fixed paraffin-embedded (FFPE) and fresh 
frozen tumor sections. DNA from FFPE sections was 
extracted using DNA/RNA FFPE kit (Qiagen Inc., Venlo, 
Netherlands) according to the manufacturer’s instructions. 
DNA from fresh frozen samples was extracted by 
following standard phenol-chloroform extraction protocol. 
For some cases the amount of DNA was inadequate to 
carry out all molecular analyses.
The participants signed an informed consent form 
with a detailed description of the study protocol. The study 
was approved by The Local Ethical Committee (Sapienza 
University of Rome, Protocol 264/12).
Mutational screening
Mutational analysis of PIK3CA, EGFR and ESR1 
was performed mainly by direct sequencing and by SSCP 
(Single Strand Conformation Polymorphism). Genomic 
DNA from each tumor sample was amplified using 
primers covering exons in which is reported to cluster the 
great majority of mutations (Supplementary Table S1), in 
particular exons 9 and 20, coding the helical and kinase 
domains of PIK3CA, respectively [61]; exons from 18 to 
24, coding kinase domain of EGFR; exons from 4 to 8, 
coding the ligand binding domain, of ESR1.
To overcome the interference of a pseudogene 
of PIK3CA, we also designed specific primers for both 
PIK3CA gene and pseudogene (Supplementary Table S1). 
DNA samples from cell lines (HCC15 and HCT16) with 
known mutations in exons 9 (c.1633G>A, p.E545K) and 
20 (HCT-116 c.3140 A>G, p.H1047R) of PIK3CA, were 
used as positive control.
Gene copy number variation analysis
PIK3CA, EGFR, ESR1 and CCND1 gene copy 
number variations (CNVs) were analyzed by Real-Time 
PCR, using TaqMan probe-based technology (Applied 
Biosystems, Foster City California, USA). The RNaseP 
as housekeeping gene and a normal male breast tissue 
sample as calibrator were used. TaqMan Copy number 
Assays (Hs02708380_cn for PIK3CA, Hs00756893_cn 
for EGFR, Hs02577150_cn for ESR1 and Hs01818912_cn 
for CCND1) and TaqMan Copy number Reference Assay 
human RNaseP, containing primers and probe mix for 
target and housekeeping genes respectively, were used 
(Applied Biosystems, Foster City California, USA). The 
analysis of relative gene expression data was performed, 
using the 2-ΔΔCt method. The fold change in studied gene 
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copy number, normalized to endogenous control, was 
calculated using RQ=2-ΔΔCt [62–63]. Values of RQ ≥2 
were considered amplified and values of RQ <0.5 were 
considered deleted.
Statistical analysis
Unsupervised hierarchical clustering was 
performed to analyze relevant clusters characterized by 
co-amplification/deletion in EGFR, PIK3CA, ESR1 and 
CCND1.
Chi square test and logistic regression models were 
performed in order to evaluate the potential associations 
between each gene alteration (mutations and CNVs) 
and clinical-pathologic features. A P value <0.05 was 
considered statistically significant. All statistical analyses 
were performed with the R software (www.r-project.org).
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